NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis → You won't believe what Citigroup just did to it's depositors (From American Alternative) (Ad) Free GTHX Stock Alerts $3.40 -0.69 (-16.87%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$3.07▼$4.2150-Day Range$3.40▼$4.9852-Week Range$1.08▼$6.14Volume2.79 million shsAverage Volume2.39 million shsMarket Capitalization$177.75 millionP/E RatioN/ADividend YieldN/APrice Target$8.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside154.9% Upside$8.67 Price TargetShort InterestBearish6.87% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.81Based on 26 Articles This WeekInsider TradingSelling Shares$44,649 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.54) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.61 out of 5 starsMedical Sector255th out of 931 stocksPharmaceutical Preparations Industry112th out of 432 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about G1 Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.87% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 26.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.2 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search Interest12 people have searched for GTHX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows9 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $44,649.00 in company stock.Percentage Held by InsidersOnly 6.11% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 24.21% of the stock of G1 Therapeutics is held by institutions.Read more about G1 Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.54) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 6.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about G1 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesMay 25, 2024 | insidertrades.comMonica R. Thomas Sells 5,826 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockMay 28 at 10:50 PM | markets.businessinsider.comBuy Rating Affirmed: G1 Therapeutics’ Cosela Shows Significant Survival Benefits in mTNBCMay 28 at 10:50 PM | markets.businessinsider.comBuy Rating Affirmed for G1 Therapeutics Amid Promising Clinical OutcomesMay 28 at 5:50 PM | msn.comG1 Therapeutics slips after new breast cancer data for lead assetMay 28 at 6:30 AM | globenewswire.comMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)May 26 at 7:06 AM | americanbankingnews.comInsider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Insider Sells 5,826 Shares of StockMay 24, 2024 | markets.businessinsider.comStrategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 TherapeuticsMay 23, 2024 | globenewswire.comG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingMay 23, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Receives "Buy" Rating from HC WainwrightMay 23, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Earns Buy Rating from Needham & Company LLCMay 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Personalis (PSNL) and G1 Therapeutics (GTHX)May 22, 2024 | finance.yahoo.comG1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitMay 22, 2024 | globenewswire.comG1 Therapeutics to Participate in TD Cowen's 5th Annual Oncology Innovation SummitMay 22, 2024 | markets.businessinsider.comG1 Therapeutics And Deimos Biosciences In License Deal For Lerociclib For Radioprotective UsesMay 22, 2024 | globenewswire.comG1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesMay 9, 2024 | msn.comG1 Therapeutics jumps amid takeover speculationMay 9, 2024 | msn.comWhat's Going On With G1 Therapeutics Stock?May 4, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?May 3, 2024 | finance.yahoo.comG1 Therapeutics First Quarter 2024 Earnings: Revenues DisappointMay 2, 2024 | markets.businessinsider.comOptimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela’s Market ExpansionMay 2, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...May 1, 2024 | finance.yahoo.comQ1 2024 G1 Therapeutics Inc Earnings CallMay 1, 2024 | markets.businessinsider.comEvaluating G1 Therapeutics: Insights From 5 Financial AnalystsMay 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | msn.comGTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024See More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/28/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+154.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-36.40% Pretax Margin-32.69% Return on Equity-74.75% Return on Assets-24.25% Debt Debt-to-Equity Ratio1.34 Current Ratio2.94 Quick Ratio2.55 Sales & Book Value Annual Sales$82.51 million Price / Sales2.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book5.00Miscellaneous Outstanding Shares52,280,000Free Float49,087,000Market Cap$177.75 million OptionableOptionable Beta1.71 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLLyell ImmunopharmaNASDAQ:LYELSilence TherapeuticsNASDAQ:SLNHarrowNASDAQ:HROWALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsMonica R ThomasSold 5,826 sharesTotal: $24,877.02 ($4.27/share)Jacobs Levy Equity Management Inc.Bought 64,790 shares on 5/16/2024Ownership: 0.723%Vanguard Group Inc.Bought 99,900 shares on 5/10/2024Ownership: 3.982%Acadian Asset Management LLCBought 375,354 shares on 5/10/2024Ownership: 0.830%SG Americas Securities LLCBought 13,536 shares on 5/7/2024Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 4 brokerages have issued 1 year target prices for G1 Therapeutics' shares. Their GTHX share price targets range from $5.00 to $12.00. On average, they anticipate the company's stock price to reach $8.67 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2024? G1 Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, GTHX shares have increased by 11.5% and is now trading at $3.40. View the best growth stocks for 2024 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,590,000 shares, an increase of 26.9% from the April 30th total of 2,830,000 shares. Based on an average daily volume of 1,380,000 shares, the short-interest ratio is currently 2.6 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.01. The firm had revenue of $14.48 million for the quarter, compared to analysts' expectations of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative trailing twelve-month return on equity of 74.75%. During the same period in the previous year, the business earned ($0.53) EPS. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.98%), Acadian Asset Management LLC (0.83%), Jacobs Levy Equity Management Inc. (0.72%), Denali Advisors LLC (0.16%), SG Americas Securities LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Monica R Thomas, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap ProfitsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.